Please assess the completion status of the following clinical trial:

Trial Title: TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI)~* Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections~Exclusion Criteria:~* Uncomplicated skin infections~* Severe sepsis or septic shock~* ABSSSI solely due to gram-negative pathogens

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TR-701 FA (Type: EXPERIMENTAL): TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
- Linezolid (Type: ACTIVE_COMPARATOR): Linezolid 600 mg tablets oral twice a day for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).